Edgewise Therapeutics, Inc.
EWTX
$14.60
$0.302.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -14.66% | -43.03% | -31.58% | -32.73% | -46.71% |
| Total Depreciation and Amortization | 6.18% | 5.52% | 18.01% | 21.13% | 15.84% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 230.94% | 314.64% | 72.26% | 66.67% | 49.73% |
| Change in Net Operating Assets | -180.30% | -105.17% | 3,553.23% | 158.01% | 1,033.63% |
| Cash from Operations | -24.84% | -32.41% | -0.47% | -24.10% | -28.99% |
| Capital Expenditure | 77.38% | 85.19% | -70.19% | -13.79% | 70.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -531.29% | 116.40% | -21.91% | 8.40% | 794.76% |
| Cash from Investing | -533.97% | 116.36% | -22.46% | 8.30% | 985.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 9,309.65% | -99.06% | -94.53% | 118,133.33% | 442.01% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 179.17% | -- | -100.00% | 0.00% | -- |
| Cash from Financing | 9,542.98% | -99.08% | -94.54% | 1,679.62% | 429.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -149.29% | 114.79% | -105.91% | 14.87% | 180.50% |